OPEN Foundation

Journal Club #28: Efficacy and Safety of Psilocybin in Treatment-Resistant Depression: Results of the EPIsoDE Trial

🗣 Lea Mertens, MSc (Clinical Psychologist, Researcher, & Licensed Psychotherapist)

⏰ Tuesday 6 October, 2026 8PM CEST (7PM BST, 2PM ET, 11AM PST)

📍 Online via Zoom

Add to Calendar

In this Journal Club session, Lea Mertens, MSc., one of the lead researchers and therapists of the EPIsoDE trial and first author of its main results paper, will present one of the largest clinical trials to date on psilocybin combined with psychotherapy for treatment-resistant depression. Having been closely involved in designing the study alongside Prof. Gerhard Gründer, Lea offers an insider’s view of how the trial was built, what it found, and what happened to patients in the months that followed.

The EPIsoDE trial looked well beyond depression scores, also examining well-being, individual differences, possible underlying mechanisms, and safety. Its results have sparked debate about how we measure depression and how we judge whether a treatment works, especially when its effects may go beyond what standard rating scales capture. Join us for a presentation and open discussion of what this study means for the future of psychedelic-assisted therapy.

READY TO ATTEND?

ATTEND FOR FREE AS A MEMBER

Unlock access to this and all exclusive live events & recordings with leading psychedelic experts and engage in real time through the OPEN Plus Tier Community Membership. Plus, enjoy a community space, a content library, discounts, and more.

ABOUT THE SPEAKER

Lea J. Mertens, MSc. is a clinical psychologist, licensed psychotherapist and clinical researcher at the Department of Molecular Neuroimaging at the Central Institute of Mental Health in Mannheim, Germany. She holds a B. Sc. in Psychology from Leiden University and a M. Sc. in Cognitive and Clinical Neuroscience, with a specialization in Neuropsychology from Maastricht University.

In her research she focuses on the clinical potential of psychedelic-assisted therapy (PAT), particularly psilocybin for depression, which she investigated as a lead-researcher and therapist in an academic phase 2b trial, the EPIsoDE trial, conducted in Germany from 2021 to 2024 as part of her PhD. Her scientific interests lie at the intersection of clinical psychology, psychopharmacology, and psychotherapy within the context of PAT. Beyond establishing the safety and efficacy of PAT, her research focuses on therapeutic mechanisms and sex-specific differences to advance personalized treatment approaches.

PLUS TIER Member Access

As a member, you can log in below and access this event or click the button at the bottom to go to the community platform.

See you there!

Community Nature Walk (Amsterdam) - September 25